Trevi Therapeutics (TRVI) Misses Q2 EPS by 1c

Trevi Therapeutics (NASDAQ: TRVI) reported Q2 EPS of ($0.12), $0.01 worse than the analyst estimate of ($0.11).

For earnings history and earnings-related data on Trevi Therapeutics (TRVI) click here.

You May Also Be Interested In

• Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance
• Pfizer (PFE) Reiterated at Neutral by Cantor Fitzgerald on Negative SV Data
• Definium Therapeutics Inc (DFTX) PT Raised to $50 at Needham